Sep 23, 2019 7:30am EDT Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia
Aug 28, 2019 7:30am EDT Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference
Aug 06, 2019 4:01pm EDT Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update
Jul 30, 2019 7:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results
Jun 13, 2019 7:30am EDT Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
May 16, 2019 7:30am EDT Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
May 07, 2019 4:01pm EDT Rigel Announces First Quarter 2019 Financial Results and Provides Company Update
Apr 30, 2019 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
